We assessed the severity of amyloid-β accumulation and white matter lesions (WML) in the brain, and their association with cognitive decline, in patients (n = 47) with Alzheimer's disease (AD). The mean cortical standardized uptake value ratio (mcSUVR) was derived from amyloid positron emission tomography, while the percentage of WML area relative to brain parenchymal area was determined using magnetic resonance imaging. Cognitive decline was positively correlated with WML severity (r = 0.50, p = 0.042) but not mcSUVR (Aβ accumulation). Managing vascular risk factors can prevent cognitive decline in patients with AD.
KasaharaHIkedaMNagashimaK, et al.Deep white matter lesions are associated with early recognition of dementia in Alzheimer's disease. J Alzheimers Dis2019; 68: 797–808.
2.
GeringDTNabaviAKikinisR, et al.An integrated visualization system for surgical planning and guidance using image fusion and an open MR. J Magn Reson Imaging2001; 13: 967–975.
3.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
4.
FolsteinMFFolsteinSEMcHughPR. Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
5.
UmemuraSArimaHArimaS, et al.The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res2019; 42: 1235–1481.
6.
OkamuraTTsukamotoKAraiH, et al.Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022. J Atheroscler Thromb2024; 31: 641–853.
7.
ArakiEGotoAKondoT, et al.Japanese Clinical practice guideline for diabetes 2019. Diabetol Int2020; 11: 165–223.
8.
SchneiderCARasbandWSEliceiriKW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods2012; 9: 671–675.
9.
FischlB. Freesurfer. Neuroimage2012; 62: 774–781.
10.
KlunkWEEnglerHNordbergA, et al.Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol2004; 55: 306–319.
11.
MathisCAWangYHoltDP, et al.Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem2003; 46: 2740–2754.
12.
IkedaMTashiroYTakaiE, et al.CSF Levels of Aβ1-38/Aβ1-40/Aβ1-42 and (11)C PiB-PET studies in three clinical variants of primary progressive aphasia and Alzheimer's disease. Amyloid2014; 21: 238–245.
13.
RoweCCNgSAckermannU, et al.Imaging beta-amyloid burden in aging and dementia. Neurology2007; 68: 1718–1725.
14.
LoprestiBJKlunkWEMathisCA, et al.Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med2005; 46: 1959–1972.
15.
McNameeRLYeeSHPriceJC, et al.Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med2009; 50: 348–355.
16.
WenhamPRPriceWHBlandellG. Apolipoprotein E genotyping by one-stage PCR. Lancet1991; 337: 1158–1159.
17.
National Institute on Aging/Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet1996; 347: 1091–1095.
18.
GodinOTzourioCMaillardP, et al.Apolipoprotein E genotype is related to progression of white matter lesion load. Stroke2009; 40: 3186–3190.
19.
McAleeseKEWalkerLGrahamS, et al.Parietal white matter lesions in Alzheimer's disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathol2017; 134: 459–473.
20.
PantoniLPoggesiAInzitariD. The relation between white-matter lesions and cognition. Curr Opin Neurol2007; 20: 390–397.
21.
Jack JrCRKnopmanDSJagustWJ, et al.Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol2010; 9: 119–128.
22.
GorelickPBScuteriABlackSE, et al.Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American stroke association. Stroke2011; 42: 2672–2713.
23.
PrinsNDvan DijkEJden HeijerT, et al.Cerebral white matter lesions and the risk of dementia. Arch Neurol2004; 61: 1531–1534.
24.
KellerJASigurdssonSKlaassenK, et al.White matter hyperintensity shape is associated with long-term dementia risk. Alzheimers Dement2023; 19: 5632–5641.
25.
MoonenJEFHaanRBosI, et al.Contributions of amyloid beta and cerebral small vessel disease in clinical decline. Alzheimers Dement2024; 20: 1868–1880.
26.
ProvenzanoFAMuraskinJTostoG, et al.White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?JAMA Neurol2013; 70: 455–461.
27.
van WestenDLindqvistDBlennowK, et al.Cerebral white matter lesions - associations with Aβ isoforms and amyloid PET. Sci Rep2016; 6: 20709.
28.
McAleeseKEMiahMGrahamS, et al.Frontal white matter lesions in Alzheimer's disease are associated with both small vessel disease and AD-associated cortical pathology. Acta Neuropathol2021; 142: 937–950.
29.
LittauJLVelillaLHaseY, et al.Evidence of beta amyloid independent small vessel disease in familial Alzheimer's disease. Brain Pathol2022; 32: e13097.
30.
SmithRCullenNCPichet BinetteA, et al.Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. Alzheimers Dement2023; 19: 2497–2507.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
